Market Overview The membranous nephropathy market is benefiting from rare disease regulatory designations that accelerate drug development timelines and incentivize pharmaceutical investment in therapies for this orphan indication. Regulatory agencies recognize the significant unmet medical need and limited treatment options for patients with refractory membranous nephropathy, offering...